Trial Profile

Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Retinal pigment epithelial cell replacement therapy-Cell Cure Neurosciences (Primary)
Indications Dry age-related macular degeneration
Focus Adverse reactions; Therapeutic Use
Sponsors Genentech; Lineage Cell Therapeutics; Roche

23 Jun 2025 According to Lineage Cell Therapeutics media release, company presented 36-month results data from this study at Clinical Trials at the Summit (CTS) 2025.
23 Jun 2025 36-month results presented in the Lineage Cell Therapeutics media release.
12 May 2025 According to a Lineage Cell Therapeutics media release, 36-month results from this trial will be presented at the Clinical Trials at the Summit (CTS) 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com